130 related articles for article (PubMed ID: 9808396)
1. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus.
Mok CC; Lau CS; Ho CT; Lee KW; Mok MY; Wong RW
Scand J Rheumatol; 1998; 27(5):342-6. PubMed ID: 9808396
[TBL] [Abstract][Full Text] [Related]
2. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial.
Buyon JP; Petri MA; Kim MY; Kalunian KC; Grossman J; Hahn BH; Merrill JT; Sammaritano L; Lockshin M; Alarcón GS; Manzi S; Belmont HM; Askanase AD; Sigler L; Dooley MA; Von Feldt J; McCune WJ; Friedman A; Wachs J; Cronin M; Hearth-Holmes M; Tan M; Licciardi F
Ann Intern Med; 2005 Jun; 142(12 Pt 1):953-62. PubMed ID: 15968009
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy in systemic lupus erythematosus.
Kreidstein S; Urowitz MB; Gladman DD; Gough J
J Rheumatol; 1997 Nov; 24(11):2149-52. PubMed ID: 9375875
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease.
Hochman J; Urowitz MB; Ibañez D; Gladman DD
Lupus; 2009 Apr; 18(4):313-7. PubMed ID: 19276299
[TBL] [Abstract][Full Text] [Related]
5. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
6. Use of exogenous estrogens in systemic lupus erythematosus.
Mok CC; Lau CS; Wong RW
Semin Arthritis Rheum; 2001 Jun; 30(6):426-35. PubMed ID: 11404826
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus.
Buyon JP
J Am Med Womens Assoc (1972); 1998; 53(1):13-7. PubMed ID: 9458619
[TBL] [Abstract][Full Text] [Related]
8. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE).
Arden NK; Lloyd ME; Spector TD; Hughes GR
Lupus; 1994 Feb; 3(1):11-3. PubMed ID: 8025579
[TBL] [Abstract][Full Text] [Related]
9. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
Mok CC; Ying SK; Ma KM; Wong CK
Lupus; 2013 Dec; 22(14):1470-8. PubMed ID: 24113197
[TBL] [Abstract][Full Text] [Related]
10. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
Vieira CS; Pereira FV; de Sá MF; Paulo LJ; Martins WP; Ferriani RA
Maturitas; 2009 Mar; 62(3):311-6. PubMed ID: 19193505
[TBL] [Abstract][Full Text] [Related]
11. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): relationship between vascular events and the use of hormone replacement therapy in postmenopausal women.
Fernández M; Calvo-Alén J; Bertoli AM; Bastian HM; Fessler BJ; McGwin G; Reveille JD; Vilá LM; Alarcón GS
J Clin Rheumatol; 2007 Oct; 13(5):261-5. PubMed ID: 17921793
[TBL] [Abstract][Full Text] [Related]
12. Menopause hormonal therapy in women with systemic lupus erythematosus.
Sánchez-Guerrero J; González-Pérez M; Durand-Carbajal M; Lara-Reyes P; Jiménez-Santana L; Romero-Díaz J; Cravioto MD
Arthritis Rheum; 2007 Sep; 56(9):3070-9. PubMed ID: 17763408
[TBL] [Abstract][Full Text] [Related]
13. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Bhattoa HP; Bettembuk P; Balogh A; Szegedi G; Kiss E
Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
[TBL] [Abstract][Full Text] [Related]
14. Do flares of systemic lupus erythematosus decline after menopause?
Mok CC; Lau CS; Ho CT; Wong RW
Scand J Rheumatol; 1999; 28(6):357-62. PubMed ID: 10665741
[TBL] [Abstract][Full Text] [Related]
15. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis.
Rojas-Villarraga A; Torres-Gonzalez JV; Ruiz-Sternberg ÁM
PLoS One; 2014; 9(8):e104303. PubMed ID: 25137236
[TBL] [Abstract][Full Text] [Related]
16. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy.
Bruce IN; Hallett DC; Gladman DD; Urowitz MB
J Rheumatol; 1999 Jul; 26(7):1490-4. PubMed ID: 10405935
[TBL] [Abstract][Full Text] [Related]
17. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.
Mok CC; To CH; Mak A; Ma KM
Arthritis Rheum; 2005 Dec; 52(12):3997-4002. PubMed ID: 16320346
[TBL] [Abstract][Full Text] [Related]
18. [Estrogen use in systemic lupus erythematosus].
Ketari S; Cherif O; Boussema F; Kochbati S; Ben Dhaou B; Rokbani L
Gynecol Obstet Fertil; 2005 Oct; 33(10):783-90. PubMed ID: 16139552
[TBL] [Abstract][Full Text] [Related]
19. Disease activity during the premenopausal and postmenopausal periods in women with systemic lupus erythematosus.
Sánchez-Guerrero J; Villegas A; Mendoza-Fuentes A; Romero-Díaz J; Moreno-Coutiño G; Cravioto MC
Am J Med; 2001 Oct; 111(6):464-8. PubMed ID: 11690572
[TBL] [Abstract][Full Text] [Related]
20. Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy.
Petri M
Lupus; 2001; 10(3):222-6. PubMed ID: 11315357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
